Aniline

Aniline

SCHEMBL2018488

NS(=O)(=O)NCCO.Nc1ccccc1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 8/20 0.48
CA1 P00915 5/20 0.48
CA12 O43570 4/20 0.48
CA14 Q9ULX7 3/20 0.48
CA7 P43166 2/20 0.48
HDAC6 Q9UBN7 2/20 0.45
PRMT1 Q99873 2/20 0.42
CA9 Q16790 3/20 0.41
CA5A P35218 2/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 2/20 0.41
BACE1 P56817 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP2D6 P10635 1/20 0.38
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA13 Q8N1Q1 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
KEAP1 Q14145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aniline SCHEMBL11571617 0.81 CA2 (0.48) CA2CA1CA12CA14CA7
Styrene SCHEMBL10482228 0.80 ALDH1A1 (0.45) CA2CA1CA12CA14CA7
SCHEMBL1012552 0.79
Aniline SCHEMBL9310054 0.76 TSHR (0.52) TSHRCYP2C19BACE1ALDH1A1
Benzene SCHEMBL11602322 0.74 CA1 (0.52) CA2CA1CA12CA14CA7
Aniline SCHEMBL3156113 0.73 TSHR (0.61) CA2CA1CA12CA14CA7
Aniline SCHEMBL28683241 0.72 TSHR (0.48) CA2CA1PRMT1CA9CA5A
Aniline SCHEMBL28143089 0.72 TSHR (0.69) TSHRCYP2C19ALDH1A1CYP2D6
Aniline SCHEMBL4582474 0.72 TSHR (0.69) CA2CA1CA12CA14CA7
SCHEMBL2563975 0.72 CYP3A4 (0.70) CA2CA1CA12CA14CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102131815-B Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate TIBOTEC PHARMACEUTICALS (IE) 2014-10-15 CN disclosed
EP-2346877-B1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE JANSSEN R & D IRELAND (IE) 2014-08-20 EP disclosed
US-8580981-B2 Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate JANSSEN R&D IRELAND (IE) 2013-11-12 US disclosed
CN-1898248-B Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARM LTD 2011-08-17 CN disclosed
EP-2346877-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE Tibotec Pharmaceuticals (IE) 2011-07-27 EP disclosed
CN-102131815-A Process for the preparation of (3R,3AS,6AR) -hexahydrofuro [2,3-B ] furan-3-yl (1S,2R) -3- [ [ (4-aminophenyl) sulfonyl ] (isobutyl) amino ] -1-benzyl-2-hydroxypropyl carbamate TIBOTEC PHARM LTD 2011-07-20 CN disclosed
US-20110160468-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE JANSSEN SCIENCES IRELAND UC (IE) 2011-06-30 US disclosed
CN-101820865-A anti-HIV tablet formulation comprising darunavir TIBOTEC PHARM LTD 2010-09-01 CN disclosed
US-7772411-B2 Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-08-10 US disclosed
US-20100189783-A1 RELATING TO ANTI-HIV TABLET FORMULATIONS JANSSEN PHARMACEUTICA NV (BE) 2010-07-29 US disclosed
WO-2010023322-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE TIBOTEC PHARMACEUTICALS (IE) 2010-03-04 WO disclosed
EP-1725566-B1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE TIBOTEC PHARM LTD (IE) 2009-06-17 EP disclosed
US-20070060642-A1 Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate JANSSEN SCIENCES IRELAND UC (IE) 2007-03-15 US disclosed
CN-1898248-A Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate TIBOTEC PHARM LTD (IE) 2007-01-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100189783-A1 RELATING TO ANTI-HIV TABLET FORMULATIONS SRI, CD4, SORD CA2 3747/4885CA1 2070/4885CA12 2236/4885
US-20110160468-A1 PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE HTR3C, HPD, HAAO CA2 3095/4885CA1 3626/4885CA12 4759/4885
US-20070060642-A1 Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate HPD, HTR3C, HAAO CA2 2351/4885CA1 3293/4885CA12 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.